CGTN
Chinese President Xi Jinping has sent New Year's greetings to Chinese people of all ethnic groups, wishing happiness and good fortune for the people and prosperity for the nation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210208005631/en/
President Xi, also general secretary of the Communist Party of China Central Committee, extended the greetings during an inspection trip in southwest China's Guizhou Province prior to the Chinese New Year, which falls on February 12 this year.
"I'd like to extend Spring Festival blessings to people of all ethnic groups across the country. I wish everyone good health, happiness for their families, successful careers, and an auspicious Year of the Ox. I also wish our great motherland, with its beautiful mountains and rivers, much prosperity," Xi said.
During his trip, President Xi visited places including the city of Bijie and the provincial capital Guiyang, as well as a village, a residential community and a supermarket, from Wednesday to Friday.
His agenda also included a meeting with project leaders and core scientists of the Five-hundred-meter Aperture Spherical Radio Telescope (FAST) project in Guizhou. The FAST, held to be the world's most sensitive radio telescope, started operation on January 11, 2020.
On Friday's meet with scientists, President Xi called for a greater focus on scientific innovation and making it a driving force for China's development.
President Xi also spoke highly of the achievements made over the past year in Guizhou Province, as he heard a work report by the Guizhou Provincial CPC Committee and the provincial government on Friday.
He pointed out innovative development is an inevitable prerequisite of fostering China's new development paradigms and urged efforts to accelerate the integration of big data and the real economy and foster strategic merging industries.
More should be done to stimulate consumption demand and develop new consumption models, so as to unleash the consumption potential to the full, Xi said.
He demanded an effective transition from consolidating poverty alleviation achievements to promoting rural vitalization.
President Xi also expressed his great confidence in the future of the region, and wished it could make new achievements in the construction of ecological civilization.
A path of high-quality development that prioritizes ecology and highlights green development should be stuck, he added, adding that achieving common prosperity is one of the most important tasks of socialist modernization; and the government should support ethnic minorities in nurturing competitive industries and prospering their cultures.
He pointed out several aspects the government should work on to bring people benefits, including education, housing, employment, diseases prevention and control system as well as safe production.
Xi also stressed that the Red Army spent the longest time in Guizhou during the Long March, leaving behind precious spiritual treasures. And the Zunyi Conference, held in Zunyi City, is a crucial turning point in the Party's history.
The meeting focused on rectifying errors and established the correct leadership of the new Central Committee, as represented by Mao Zedong, Xi said, making it still matter today.
Original article：here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210208005631/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom